Medical Treatment ofDeep Vein Thrombosis
The problems of deep vein thrombosis (DVT) and its sequele continue to be frequently encountered in clinical practice but opinions vary as to their significance. While many believe that most episodes are benign events, several thousand deaths are recorded each year where venous thrombosis or pulmonary embolism are considered to be the major causal event.
Over the past few years there has been increasing interest in this condition, its incidence, diagnosis and treatment. Obviously prevention is the best approach in situations where there is known to be a high incidence of venous thrombosis, e.g. post surgical intervention or post coronary thrombosis, and recent studies have shown promising results using heparin or dextran. Yet these methods will never eradicate the problem completely. Deep venous thrombosis of leg veins will continue to develop unexpectedly in the hospital patient or in the ambulant apparently normal person as a result of trivial trauma, the contraceptive pill, early neoplasia or from no detectable cause.
Suspicion grows that the venous thrombosis is not one particular entity but that the postsurgical thrombosis may have a different pathogenesis and morbidity to the spontaneous and often recurrent ileofemoral thrombosis of unknown etiology and these differences require further study.
Recent prospective studies using 1251 fibrinogen have shown the actual incidence of DVT is higher than clinical assessment might suggest. Similarly phlebography, providing objective evidence of the existence and size of a thrombus, has revealed that clinical assessment is often very misleading.
It is current practice to treat DVTs, once suspected or proved, by anticoagulant therapy. While Sevitt & Gallagher (1952) demonstrated the value of oral anticoagulants in the prevention of pulmonary embolus following fractures of the lower limb, there is little or no evidence that anticoagulants have any effect on the thrombus itself. It would appear to be unethical to give no treatment (Barritt & Jordan 1961) ; therefore, a true controlled study of the effect of anticoagulants has never been properly done.
Recent trials, comparing conventional anticoagulant therapy with thrombolytic agents and monitoring the effect by phlebography before and after treatment, show that significant thrombolysis takes place only when induced fibrinolysis is produced by streptokinase (Kakkar et al. 1969 , Kakkar 1973 . Further in the SK treated group valve function was preserved.
Similar trials in Oxford have shown disappointing results when ancrod (Arvin) and heparin were compared, but significant thrombolysis took place using streptokinase. The age of the thrombus has little or no effect on these results. Streptokinase might be considered the treatment of choice in terms of venographic improvement, but it has been impossible to prove that this has any real long-term benefit or is life saving in relation to the small numbers included in these trials. Equally, however, it has not been proved that successful thrombolysis has no longterm benefit (Davies et al. 1972 , Tibbutt et al. 1974 .
The problem of the medical treatment of DVT is still with us and this will not be solved without a more detailed study of much larger groups of patients. We shall continue to treat each case on individual subjective opinion, perhaps selecting streptokinase for those with phlebographically proven ileofemoral vein thrombosis of short duration.
Alternatively, improving surgical techniques may result in thrombectomy being the treatment ofchoice.
